Reishi: the evidence.

How to read this page

We have tried to describe the state of the research rather than the state of the marketing, which means this page is less exciting than most pages about this mushroom. Nothing here is medical advice, and nothing here should be read as a claim that this mushroom treats, prevents or cures any condition. If you are considering a supplement — particularly alongside prescription medication — that is a conversation with a clinician, not a website.

What reishi is, and why it is different

Ganoderma lucidum — reishi, lingzhi — is not a culinary mushroom. It is woody and intensely bitter, and it has been prepared as a tea, decoction or tincture in Chinese and Japanese traditions for a very long time. The species page covers preparation; this page covers evidence.

Its chemistry is unusual among the functional mushrooms because it has two distinct compound families that matter: water-soluble polysaccharides including beta-glucans, and alcohol-soluble triterpenes — the ganoderic acids that give reishi its bitterness. This is why “dual-extracted” is a meaningful phrase for reishi specifically and often marketing elsewhere.

The state of the research

Reishi has one of the largest publication counts of any medicinal fungus, and that volume is easy to mistake for strength of evidence. The reality:

• Extensive preclinical literature — cell and animal studies on immune signalling, inflammatory markers, and a range of other endpoints.
• Human trials that are typically small, often not well controlled, frequently conducted with non-standardised preparations, and heavily concentrated in a few research traditions.
• Systematic reviews that repeatedly reach the same conclusion: insufficient evidence to support clinical recommendations, and a call for larger and better-designed trials.

The areas where human research is most often cited are sleep quality, fatigue and general wellbeing, and results there are inconsistent and rely substantially on self-reported measures.

A large number of papers is not the same as a strong body of evidence. Reishi has the former; the honest reading is that it does not yet have the latter.

The quality problem

This is the practical issue with reishi more than with any other functional mushroom. Independent testing of commercial products has repeatedly found wide variation in active content, products containing little identifiable reishi, and mycelium-on-grain sold as fruiting body.

If you are buying reishi, the label needs to state: species in Latin, fruiting body or mycelium, extraction method, extract ratio, and beta-glucan percentage as distinct from total polysaccharide. Anything vaguer is not a product you can reason about. See functional mushroom forms.

Safety and interactions — the important part

Reishi is generally well tolerated, but it has genuine interaction concerns that are more substantial than for most mushrooms:

• Anticoagulants and antiplatelet drugs. Reishi may affect platelet aggregation. This is the interaction most often flagged, and it matters.
• Antihypertensives and diabetes medication — possible additive effects reported.
• Immunosuppressants — a mushroom studied for immune modulation is a reasonable thing to be cautious about if you are deliberately suppressing immune function.
• Before surgery — discontinue and tell your surgical team.
• Liver effects have been reported in isolated cases, generally involving powdered products.
• Pregnancy and breastfeeding — insufficient safety data.

If you take any regular medication, ask a pharmacist or doctor before starting reishi. This is not a legal disclaimer; it is the single most useful sentence on this page.

Where we stand

Reishi is a fascinating organism with a serious traditional lineage and a research literature that has not yet resolved into clear human evidence. We grow it, we sell it fresh as antler forms for people making their own tinctures, and dried for tea — and we describe it as what it is: a traditional preparation with promising but unsettled science, not a treatment for anything.

Common questions